Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1373/clinchem.2013.202556PMID 24379312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women’s Health Initiative hormone therapy clinical trials

  2014cited by this paper
• Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

  2013cited by this paper
• The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy.

  2013cited by this paper
• Relationships of Coronary Heart Disease With 27-Hydroxycholesterol, Low-Density Lipoprotein Cholesterol, and Menopausal Hormone Therapy

  2012cited by this paper
• Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial

  2012cited by this paper
• Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk

  2012cited by this paper
• Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy

  2012cited by this paper
• A Sustained Decline in Postmenopausal Hormone Use: Results From the National Health and Nutrition Examination Survey, 1999–2010

  2012cited by this paper
• Hormone Therapy, Estrogen Metabolism, and Risk of Breast Cancer in the Women's Health Initiative Hormone Therapy Trial

  2012cited by this paper
• Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome A nested case-control study within the Women’s Health Initiative randomized clinical trials

  2012cited by this paper
• Estrogen Receptor Polymorphisms and the Vascular Effects of Hormone Therapy

  2011cited by this paper
• Postmenopausal hormone therapy: an Endocrine Society scientific statement.

  2010cited by this paper
• Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling

  2010cited by this paper
• Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study

  2010cited by this paper
• Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women

  2009cited by this paper
• Variation in the FGFR2 Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer

  2009cited by this paper
• Frequently asked questions

  2009cited by this paper
• Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy.

  2008cited by this paper
• Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy.

  2008cited by this paper
• Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events.

  2008cited by this paper
• Can Biomarkers Identify Women at Increased Stroke Risk? The Women's Health Initiative Hormone Trials

  2007cited by this paper
• Estrogen therapy and coronary-artery calcification.

  2007cited by this paper
• Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women

  2007cited by this paper
• Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

  2007cited by this paper
• Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study

  2007cited by this paper
• Faculty Opinions recommendation of Venous thrombosis and conjugated equine estrogen in women without a uterus.

  2006cited by this paper
• Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

  2006cited by this paper
• Postmenopausal hormone therapy: new questions and the case for new clinical trials

  2006cited by this paper
• Hormone Therapy and Coronary Heart Disease: The Role of Time since Menopause and Age at Hormone Initiation

  2006cited by this paper
• Brief report: Coronary heart disease events associated with hormone therapy in younger and older women

  2006cited by this paper
• Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative

  2006cited by this paper
• Estrogen plus progestin and risk of venous thrombosis.

  2005influential reference
• Hormone Therapy in Postmenopausal Women

  2005cited by this paper
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• Estrogen plus progestin and risk of venous thrombosis.

  2004cited by this paper
• Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

  2004cited by this paper
• Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women.

  2003cited by this paper
• Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

  2003cited by this paper
• Estrogen plus progestin and the risk of coronary heart disease.

  2003cited by this paper
• Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial

  2003cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Estrogen replacement therapy, atherosclerosis, and vascular function.

  2002cited by this paper
• Subgroup Interactions in the Heart and Estrogen/Progestin Replacement Study: Lessons Learned

  2002cited by this paper
• Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS)

  2002cited by this paper
• Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

  2002cited by this paper
• Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

  2002cited by this paper
• Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.

  2002cited by this paper
• Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II)

  2002cited by this paper
• Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis: A Randomized, Controlled Trial

  2001cited by this paper
• Estrogen in the Prevention of Atherosclerosis

  2001cited by this paper
• Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study

  2000cited by this paper
• Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.

  2000cited by this paper
• Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.

  2000cited by this paper
• A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease

  2000cited by this paper
• The Heart and Estrogen/Progestin Replacement Study

  1999cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Inflammatory, Lipid, Thrombotic, and Genetic Markers of Coronary Heart Disease Risk in the Women's Health Initiative Trials of Hormone Therapy

  year unknowncited by this paper

• Estrogen rapid effects: a window of opportunity for the aging brain?

  2022cites this paper
• Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.

  2021cites this paper
• Managing menopausal vasomotor symptoms in older women.

  2021cites this paper
• Cardiovascular risk assessment: just do it.

  2021cites this paper
• A hypertension patient-derived iPSC model demonstrates a role for G protein-coupled estrogen receptor in hypertension risk and development

  2020cites this paper
• The Women's Health Initiative trials of menopausal hormone therapy: lessons learned.

  2020cites this paper
• A hypertension patient derived induced pluripotent stem cell model demonstrates a role for GPER in hypertension risk and development.

  2020cites this paper
• Approach to Managing a Postmenopausal Patient.

  2020cites this paper
• The effect of formononetin on the proliferation and migration of human umbilical vein endothelial cells and its mechanism.

  2019cites this paper
• Menopausal hormone therapy: modern state of the problem

  2019cites this paper
• Risk and possibilities of preventing cardiovascular diseases in women in peri- and postmenopause

  2019cites this paper
• Menopausal Treatment

  2019cites this paper
• Perspectives on counseling patients about menopausal hormone therapy: strategies in a complex data environment

  2018cites this paper
• [Menopause: Hypertension and vascular disease].

  2018cites this paper
• Menopausia: hipertension arterial y enfermedad vascular

  2018cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.

  2017cites this paper
• Exercises improve body composition, cardiovascular risk factors and bone mineral density for menopausal women: A systematic review and meta-analysis of randomized controlled trials.

  2017cites this paper
• Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy

  2017cites this paper
• Comparison of the effect and safety of Kuntai capsule and hormone replacement therapy in patients with perimenopausal syndrome: a systematic review and Meta-analysis.

  2017cites this paper
• Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relations.

  2017cites this paper
• Voluntary Running Attenuates Metabolic Dysfunction in Ovariectomized Low-Fit Rats

  2017cites this paper
• Phytoestrogen‐Rich Natural Preparation for Treatment of Climacteric Syndrome and Atherosclerosis Prevention in Perimenopausal Women

  2017cites this paper
• Comparison of the effect and safety of Kuntai capsule and hormone replacement therapy in patients with perimenopausal syndrome: a systematic review and Meta-analysis.

  2017cites this paper
• A conversation about hormone therapy: is there an appropriate dose, route, and duration of use?

  2017cites this paper
• A relative L‐arginine deficiency contributes to endothelial dysfunction across the stages of the menopausal transition

  2017cites this paper
• The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset?

  2016cites this paper
• Review of the effect of intravenous lipid emulsion on laboratory analyses

  2016cites this paper
• Soy Isoflavone Protects Myocardial Ischemia/Reperfusion Injury through Increasing Endothelial Nitric Oxide Synthase and Decreasing Oxidative Stress in Ovariectomized Rats

  2016cites this paper
• Management of Menopausal Symptoms.

  2015cites this paper
• Cardiac autonomic changes after 40 hours of total sleep deprivation in women.

  2015cites this paper
• Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society

  2015cites this paper
• Metabolic Syndrome and Menopause: Pathophysiology, Clinical and Diagnostic Significance.

  2015cites this paper
• Female rats selectively bred for high intrinsic aerobic fitness are protected from ovariectomy-associated metabolic dysfunction.

  2015cites this paper
• Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.

  2015influential citation
• Women, the menopause, hormone replacement therapy and coronary heart disease

  2015cites this paper
• Significant role of estrogen in maintaining cardiac mitochondrial functions.

  2015cites this paper
• Effects of postmenopausal hot flushes and hormone therapy on quality of life and cardiovascular autonomic function

  2014cites this paper
• What's different about women's health?

  2014cites this paper
• The WISEWOMAN Program: Smoking Prevalence and Key Approaches to Smoking Cessation Among Participants, July 2008–June 2013

  2014cites this paper
• Current recommendations: what is the clinician to do?

  2014cites this paper
• Competency in Menopause Management: Whither Goest the Internist?

  2014cites this paper
• Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol.

  2014cites this paper
• Risk of vascular disease in premenopausal women with diabetes mellitus.

  2014cites this paper